Discontinuation of imatinib therapy after achieving a molecular response.
about
Ubp43 regulates BCR-ABL leukemogenesis via the type 1 interferon receptor signalingThe concept of treatment-free remission in chronic myeloid leukemiaMolecular mechanisms for survival regulation of chronic myeloid leukemia stem cellsInhibition of STAT5: a therapeutic option in BCR-ABL1-driven leukemiaEffect of cellular quiescence on the success of targeted CML therapyPTEN regulates BCRP/ABCG2 and the side population through the PI3K/Akt pathway in chronic myeloid leukemiaBCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinibImatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.Successful use of National Cancer Registry data to monitor the effective use of imatinib for treating chronic myeloid leukaemia.Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells.Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate.Bcl2 is not required for the development and maintenance of leukemia stem cells in mice.Characterization of chronic myeloid leukemia stem cells.The paradox of response and survival in cancer therapeuticsGene expression changes associated with progression and response in chronic myeloid leukemia.NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemiaPML targeting eradicates quiescent leukaemia-initiating cells.Chronic myelogenous leukemia: treatment and monitoring.E- and p-selectins are essential for repopulation of chronic myelogenous and chronic eosinophilic leukemias in a scid mouse xenograft modelImatinib spells BAD news for Bcr/abl-positive leukemiasRight on target: eradicating leukemic stem cells.Role of Pten in leukemia stem cellsChronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy.Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatmentCancer Stem Cells: From Bench to BedsideMolecular monitoring of chronic myelogenous leukemia: identification of the most suitable internal control gene for real-time quantification of BCR-ABL transcripts.Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML.Essential role for telomerase in chronic myeloid leukemia induced by BCR-ABL in mice.Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia.Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing.Evolving molecular therapy for chronic myeloid leukaemia--are we on target?Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606.Emerging drugs in chronic myelogenous leukaemia.Applying the discovery of the Philadelphia chromosome.Re-emergence of interferon-α in the treatment of chronic myeloid leukemiaCancer stem cells with genetic instability: the best vehicle with the best engine for cancer.Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy.
P2860
Q24685070-C4D13349-0D61-49EE-BE0E-A003388C6E5AQ26748733-6744AEAD-C595-460D-9A99-1A3624DED814Q26828528-6E50FD24-B8AD-4254-AF65-2A004D6C5A50Q27004027-7624EFA6-30FA-4B19-B6FB-16A5BAC5AB6DQ28469312-29AB0CA6-A2C7-46F2-AEFA-EC9B54388833Q28540547-2F656B0D-329E-4984-AAA2-323E64C7F8EFQ30156840-76B585CC-5F56-46F3-933F-8050FD0A070AQ30873646-01972A0C-202D-497C-B0B7-E86DC88BD975Q33285468-3523C271-9051-496B-A8E3-3D2601715D6AQ33368010-642681F0-966C-48F1-A2C8-909DCAB07E90Q33566582-E846C991-6D34-4EF6-93A8-3059462E01CEQ33747277-9FE215D8-0FE5-4183-80B4-3910CAA30240Q33866597-64AB8F6C-0FA2-4B29-BBD4-E8F2DD5DF5C5Q33947776-DCED70E7-F60E-40A7-B2B5-A3EC50B259CEQ34443802-0E9D5F8F-6B5C-46D8-849E-68BF1DC151B6Q34449433-F98D776D-5DE0-4597-A738-0248DA8F2569Q34479561-F0692BFA-16CE-4A9E-8038-AD2C6153520FQ34522789-0DB4F8CD-F783-4B21-A8A0-C1517A460BACQ34591761-8634DDB7-88DC-4C3F-8039-C4FDF818A441Q34617628-85C90B97-60CF-47C5-9062-3398F149F8BEQ34906157-EBC365CA-3007-4263-BD80-1A6C9C583420Q35075394-6F23691F-13F5-4840-A918-3F810E509429Q35132225-FAF153AB-A0AB-4EDC-B85C-36DA696CD735Q35169570-8DB04727-C0A8-4E00-BF12-215831DB3240Q35640320-40EC1E0F-4AB6-488B-AA92-3B7F7A6CE763Q35663526-BD6A4732-8779-4317-A4F3-EBED9ED3AC1DQ35765724-1508478D-DFAA-460F-BD7C-93340282DEF2Q35790163-97F0F930-F0D0-4740-98E8-BCE392BD771DQ35903385-A6CDB9AE-22AD-4B1D-BC18-B14738448244Q35987068-4133EE7C-AC22-4B77-9614-32242615AA31Q36006401-FA4DF95E-ED88-48F3-9336-CDCB944EF3ACQ36141619-41935942-61BD-4342-9C82-3657E5D84312Q36276288-AFE95825-6380-49B7-A29C-2E7E7B6BC08DQ36328410-BE756EDA-EF49-4537-9680-04990B3B3909Q36445910-8010F229-9DA8-4736-A871-FD2410CACA5EQ36634266-95078E73-CF1D-4F3E-B906-4BC635B68C72Q36900109-96887BD1-3D7B-4CB6-810A-95F9A027FAAFQ36989407-19BDFE63-5E44-47C3-BACA-2CC9B5447FB7Q36996117-97E4B1EB-00AF-451C-B1B9-D51902FBE96DQ37060530-A7F29F5C-2A7C-46CA-B927-38C11BFB3281
P2860
Discontinuation of imatinib therapy after achieving a molecular response.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Discontinuation of imatinib therapy after achieving a molecular response.
@en
Discontinuation of imatinib therapy after achieving a molecular response.
@nl
type
label
Discontinuation of imatinib therapy after achieving a molecular response.
@en
Discontinuation of imatinib therapy after achieving a molecular response.
@nl
prefLabel
Discontinuation of imatinib therapy after achieving a molecular response.
@en
Discontinuation of imatinib therapy after achieving a molecular response.
@nl
P50
P1433
P1476
Discontinuation of imatinib therapy after achieving a molecular response.
@en
P304
P356
10.1182/BLOOD-2004-04-1335
P407
P577
2004-10-01T00:00:00Z